≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

This is a non-core endpoint: only basic statistics are computed.

Malignant neoplasm of ureter

DOID Endpoint Browser

C3_URETER

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

557745

1. Apply sex-specific rule

None

557745

2. Check conditions

None

557745

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Cause of death: ICD-10 — C66
  • Cause of death: ICD-9 — 189[2-3]
  • Cause of death: ICD-8 — 1892
  • Cancer registry: Topography ICD-O-3 — C66
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 3

2 out of 7 registries used, show all original rules.

112

4. Check minimum number of events

None

112

5. Include endpoints

None

112

6. Filter based on genotype QC (FinnGen only)

102

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF9

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 102 35 67
Unadjusted period prevalence (%) 0.02 0.01 0.03
Median age at first event (years) 74.38 73.79 74.68

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
109
Matched controls
1090
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C66
ICD-10 Finland
Malignant neoplasm of ureter
+∞
116.5
90
*
8120/3-C66.9
ICD-O-3
Transitional cell carcinoma, NOS, of ureter
+∞
116.5
90
*
UKC02
NOMESCO Finland
Cystoscopy
71.3
89.8
98
121
R31
ICD-10 Finland
Unspecified haematuria
25.0
67.8
74
85
UKB02
NOMESCO Finland
Retrograde ureteroscopy
797.3
52.0
47
*
D41.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Ureter
+∞
47.4
42
*
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
46.2
41
*
130
Kela drug reimbursment
Malignant tumour
+∞
42.5
38
*
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
112.0
40.5
42
6
JN4AD
NOMESCO Finland
Body CT examination
16.5
39.7
40
37
KCD02
NOMESCO Finland
Transurethral resection of bladder
276.1
38.5
37
*
C67.9
ICD-10 Finland
Malignant neoplasm: Bladder, unspecified
+∞
34.2
31
*
KAC21
NOMESCO Finland
Percutaneous endoscopic nephroureterectomy
+∞
34.2
31
*
KAC20
NOMESCO Finland
Nephroureterectomy
+∞
33.0
30
*
Z51.5
ICD-10 Finland
Palliative care
15.3
32.7
33
30
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
60.8
27.3
31
7
KCD05
NOMESCO Finland
Excision of bladder lesion during urinary tract endoscopy with photodynamic diagnosis (PDD)
177.3
27.0
27
*
H02AB02
ATC
dexamethasone; systemic
160.3
24.7
25
*
TPH07
NOMESCO Finland
Cathetrisation of artery
7.9
21.9
38
69
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
21.6
20
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
9.4
19.6
27
37
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
19.3
18
*
D41.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bladder
54.5
19.1
22
5
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
18.2
17
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
18.2
17
*
B01AB10
ATC
tinzaparin; parenteral
8.4
18.0
27
41
JN3AD
NOMESCO Finland
Abdominal CT examination
7.3
17.9
32
59
UKC05
NOMESCO Finland
Cystoscopy and bladder biopsy
75.8
17.4
19
*
A03FA01
ATC
metoclopramide; systemic, rectal
6.6
17.3
35
73
KH1AD
NOMESCO Finland
CT of urinary organs
18.5
16.9
26
18
WZC00
NOMESCO Finland
Treatment plan or consultation
5.3
16.4
49
145
KBV12
NOMESCO Finland
Transluminal endoscopic removal of stent from ureter
99.8
16.1
17
*
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
+∞
16.0
15
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.4
15.4
31
64
WX402
NOMESCO Finland
General anaesthesia
5.4
14.6
38
99
WX302
NOMESCO Finland
Thoracal epidural anesthesy
19.6
14.1
21
13
UKA02
NOMESCO Finland
Retrograde ureteronephroscopy
+∞
13.8
13
*
WX408
NOMESCO Finland
General anesthesy, balanced
4.9
13.8
41
119
XX3DW
NOMESCO Finland
Time consuming IT work
14.2
13.6
23
20
C65
ICD-10 Finland
Malignant neoplasm of renal pelvis
+∞
12.7
12
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
13.5
12.7
22
20
WF049
NOMESCO Finland
Radiotherapy of metastasis
146.1
12.7
13
*
WZC30
NOMESCO Finland
Teaching
5.2
12.4
31
77
N02AA05
ATC
oxycodone; systemic
4.7
12.1
36
103
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
4.4
12.0
41
131
A04AA01
ATC
ondansetron; systemic, rectal
17.7
11.8
18
12
KBJ10
NOMESCO Finland
Cutaneous ureteroenterostomy
+∞
11.7
11
*
C67.2
ICD-10 Finland
Malignant neoplasm: Lateral wall of bladder
+∞
11.7
11
*
TKC20
NOMESCO Finland
Catheterisation of bladder
6.1
11.6
23
46
J01MA02
ATC
ciprofloxacin; systemic
4.0
11.3
67
313
B01AB05
ATC
enoxaparin; parenteral
3.9
11.1
53
213
KBD00
NOMESCO Finland
Partial excision of ureter
+∞
10.6
10
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
10.6
10
*
N13.1
ICD-10 Finland
Hydronephrosis with ureteral stricture, not elsewhere classified
+∞
10.6
10
*
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
+∞
10.6
10
*
JN4BD
NOMESCO Finland
Extensive body CT
9.0
10.0
21
28
ZXE20
NOMESCO Finland
More than three and less than five hours
4.5
9.8
28
77
JN4CD
NOMESCO Finland
Very extensive body CT
19.8
9.7
14
8
KC1GB
NOMESCO Finland
Cystography with X-ray
109.1
9.6
10
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
9.5
9
*
116
Kela drug reimbursment
Prostate cancer
+∞
9.5
9
*
KBB00
NOMESCO Finland
Biopsy of ureter
+∞
9.5
9
*
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
15.6
9.5
15
11
KCD32
NOMESCO Finland
Cystoscopic destruction of tumour of bladder
40.3
9.2
11
*
KH1CD
NOMESCO Finland
Very extensive urinary tract ultrasound examination
40.3
9.2
11
*
ZXE00
NOMESCO Finland
One hour or less
3.4
8.9
56
261
KBV15
NOMESCO Finland
Cystoscopic change of ureteral stent
54.5
8.8
10
*
KBH20
NOMESCO Finland
Replantation of ureter
97.3
8.5
9
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
8.4
8
*
L02AE02
ATC
leuprorelin; implant, parenteral
+∞
8.4
8
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
14.5
8.1
13
10
ZXE10
NOMESCO Finland
More than one and less than three hours
3.1
7.8
51
240
XKD00
NOMESCO Finland
Uroflowmetry
3.4
7.7
35
132
KCW96
NOMESCO Finland
Other operations on bladder
85.7
7.5
8
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
85.7
7.5
8
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
7.4
7
*
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
+∞
7.4
7
*
A79
ICPC
Malignancy NOS
+∞
7.4
7
*
WF002
NOMESCO Finland
Radical radiotherapy
74.0
6.5
7
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.1
6.4
33
133
J01MA12
ATC
levofloxacin; systemic
3.2
6.4
32
127
J01EA01
ATC
trimethoprim; systemic
3.0
6.3
38
167
8130/2-C66.9
ICD-O-3
Papillary urothelial carcinoma, non-invasive of ureter
+∞
6.3
6
*
KCC10
NOMESCO Finland
Cystoprostatectomy
+∞
6.3
6
*
ZX136
NOMESCO Finland
Intravesicalis
+∞
6.3
6
*
R82.8
ICD-10 Finland
Abnormal findings on cytological and histological examination of urine
+∞
6.3
6
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
6.3
6
*
PJD54
NOMESCO Finland
Block dissection of iliac lymph nodes
+∞
6.3
6
*
L03AA02
ATC
filgrastim; parenteral
+∞
6.3
6
*
A04AD12
ATC
aprepitant; systemic
+∞
6.3
6
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
6.3
6
*
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
+∞
6.3
6
*
KBV00
NOMESCO Finland
Insertion of stent into ureter
+∞
6.3
6
*
Z08.0
ICD-10 Finland
Follow-up examination after surgery for malignant neoplasm
+∞
6.3
6
*
KA3GB
NOMESCO Finland
Retrograde pyelography
+∞
6.3
6
*
KA3EB
NOMESCO Finland
Antegrade pyelography
+∞
6.3
6
*

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
68
31
56.66
100.43
5.9
1.8
—
—
—
0
0
34
56
8.37
21.32
2.0
1.1
—
—
—
0
0
74
289
5.86
18.08
7.0
3.5
—
—
—
0
0
62
230
4.93
15.55
3.5
1.6
—
—
—
0
0
71
310
4.70
14.00
8.5
3.2
602.88
244.56
e6/l
0.44
62
237
63
265
4.26
12.75
8.1
3.2
0.37
0.40
e6/l
0.06
56
189
72
337
4.35
12.45
9.3
4.1
129.97
95.68
e6/l
0.31
63
243
23
25
11.34
12.25
1.7
1.1
—
—
—
0
0
74
361
4.27
11.89
4.4
2.4
—
—
estimate
—
0
0
60
255
4.01
11.73
6.1
4.0
—
—
—
0
0
48
189
3.75
10.23
5.6
2.7
465.16
540.88
mosm/kgh2o
2.43
43
158
40
142
3.87
9.88
8.6
5.4
105.35
104.11
mmol/l
0.91
40
142
23
54
5.13
9.67
3.3
1.4
5.34
2.97
ug/l
0.51
18
44
77
423
3.79
9.60
11.4
3.9
9.16
12.44
umol/l
4.59
77
395
77
438
3.58
8.77
12.9
5.5
4.21
4.48
e9/l
0.52
64
370
79
478
3.37
7.70
9.1
6.0
1.20
1.21
mmol/l
0.51
72
407
53
258
3.05
7.55
3.4
2.0
—
—
—
0
0
76
473
3.00
6.61
24.6
18.9
1.32
1.40
inr
0.57
66
388
73
454
2.84
6.19
7.3
4.3
0.00
0.00
estimate
-0.00
19
89
52
277
2.68
5.93
5.5
3.9
7.38
7.40
ph
1.69
39
196
31
126
3.04
5.87
5.2
2.6
0.82
0.82
mmol/l
0.02
31
116
71
447
2.69
5.69
7.3
4.3
0.00
0.00
estimate
-0.00
19
84
71
458
2.58
5.24
7.5
4.2
0.00
0.05
estimate
0.49
19
83
61
367
2.50
5.22
4.7
5.1
2.47
3.14
%
1.36
56
331
29
121
2.90
5.19
9.1
6.5
-1.79
1.24
mmol/l
2.62
23
103
22
78
3.28
5.19
10.5
8.1
—
—
—
0
0
19
62
3.50
5.08
11.2
7.7
0.34
0.66
%
4.14
19
62
64
403
2.42
4.84
4.8
5.0
0.66
0.62
e9/l
0.55
52
334
33
153
2.66
4.82
8.5
3.4
0.72
1.37
e6/l
0.60
25
74
29
126
2.77
4.80
9.4
6.3
7.41
7.42
ph
0.35
11
79
64
408
2.38
4.64
4.8
5.0
0.04
0.04
e9/l
0.54
54
340
64
410
2.36
4.56
5.0
5.1
2.26
1.76
e9/l
0.44
53
346
16
50
3.58
4.54
6.1
3.5
1.63
0.25
%
—
8
12
19
67
3.22
4.49
11.3
7.4
0.76
1.37
%
2.60
19
67
58
364
2.27
4.24
5.8
4.0
6.24
6.21
ph
0.06
36
197
64
421
2.26
4.15
4.9
5.0
0.17
0.21
e9/l
1.10
53
351
16
55
3.24
3.93
6.8
3.6
0.00
0.00
%
—
10
9
21
86
2.79
3.83
5.2
2.5
0.09
0.57
e6/l
2.07
21
80
17
62
3.06
3.79
1.4
1.4
—
—
—
0
0
9
16
6.02
3.74
5.8
3.3
—
—
—
0
0
19
75
2.86
3.70
5.9
2.8
—
—
—
0
0
43
251
2.18
3.64
7.6
4.1
0.00
0.00
estimate
-0.00
14
77
6
6
10.48
3.54
1.3
2.3
—
—
—
0
0
15
54
3.06
3.41
6.3
3.5
0.00
0.09
%
—
7
11
52
338
2.03
3.24
7.7
4.2
0.07
0.00
estimate
0.47
14
63
28
143
2.29
3.23
5.7
3.7
—
—
—
0
0
15
57
2.89
3.11
6.3
3.4
1.14
1.07
%
—
7
14
6
8
7.85
3.09
1.2
1.3
23.67
20.57
ng/l
—
6
8
18
77
2.60
3.01
3.3
2.4
11.48
6.46
umol/l
0.34
18
71
17
72
2.61
2.90
1.4
1.2
—
—
—
0
0
28
150
2.17
2.86
2.4
2.7
9.97
12.73
umol/l
1.44
28
138
39
242
1.95
2.67
7.6
3.6
0.27
0.00
estimate
0.47
11
65
32
185
2.03
2.67
3.1
2.1
2.47
2.43
mmol/l
0.80
26
154
21
103
2.29
2.63
1.6
1.8
—
—
—
0
0
42
275
1.86
2.41
4.0
4.9
—
—
—
0
0
25
137
2.07
2.39
2.4
2.7
1.97
2.20
g/l
0.94
25
124
17
81
2.30
2.27
5.9
1.6
403.47
410.80
nmol/l
0.04
17
74
10
39
2.72
2.00
2.0
1.8
—
—
—
0
0
26
154
1.90
1.99
1.9
1.6
30.00
29.74
s
0.10
26
147
9
33
2.88
1.98
1.0
1.4
—
—
—
0
0
47
346
1.63
1.67
4.7
4.2
—
—
—
0
0
12
57
2.24
1.62
6.5
7.6
24.10
25.24
mmol/l
0.30
12
57
29
191
1.71
1.56
1.4
1.3
—
—
—
0
0
5
15
3.44
1.54
1.4
1.7
17.00
76.60
u/ml
—
5
15
92
812
1.85
1.53
29.1
15.4
—
—
—
0
0
13
68
2.04
1.40
4.2
3.9
—
—
—
0
0
6
23
2.70
1.38
1.7
1.3
127.65
286.10
ug/g
—
6
10
46
350
1.54
1.37
26.7
11.2
0.00
0.00
e9/l
0.50
32
279
5
17
3.03
1.37
5.8
2.9
5.26
5.13
kpa
—
5
17
5
17
3.03
1.37
5.8
2.9
8.96
8.04
kpa
—
5
17
55
436
1.53
1.36
2.0
2.3
98.03
93.59
pmol/l
0.29
30
213
12
62
2.05
1.33
9.0
3.6
—
—
—
0
0
6
25
2.48
1.26
2.0
2.8
54.35
62.74
%
—
6
25
19
118
1.74
1.25
2.6
3.3
5.59
5.76
kpa
0.27
19
113
5
19
2.71
1.23
1.0
1.3
—
—
—
0
0
7
31
2.34
1.12
1.1
1.1
—
79.40
—
0
10
31
228
1.50
1.05
2.1
2.6
358.85
365.31
umol/l
0.10
26
191
20
133
1.62
1.03
1.6
2.1
1.71
1.62
%
0.15
20
114
6
28
2.21
0.93
8.5
3.2
7.43
7.41
ph
—
6
28
45
364
1.40
0.92
3.0
4.2
5.83
7.41
mg/mmol
0.36
32
233
10
56
1.87
0.91
1.5
1.5
—
—
—
0
0
44
355
1.40
0.91
2.1
3.4
6.74
7.33
mmol/l
0.54
35
295
16
104
1.63
0.91
6.7
2.5
4.97
5.08
e9/l
0.03
16
82
18
122
1.57
0.87
2.7
3.3
7.37
7.39
ph
0.55
12
72
12
73
1.72
0.85
1.5
1.5
—
—
—
0
0
9
58
1.60
0.72
1.6
2.0
0.64
0.56
%
—
9
58
43
359
1.33
0.69
2.2
3.5
32.48
53.18
mg/l
1.05
30
233
10
62
1.67
0.67
2.6
3.6
22.34
24.06
mmol/l
—
10
62
5
29
1.76
0.64
5.6
3.8
—
—
—
0
0
50
430
1.30
0.64
4.6
4.5
1.96
2.11
ug/l
0.10
45
378
81
745
1.34
0.62
5.7
5.4
2.11
1.95
mu/l
0.41
76
661
8
51
1.61
0.62
4.5
2.7
—
—
—
0
0
10
64
1.62
0.61
3.4
1.4
—
—
—
0
0
0
21
0.00
0.60
0.0
1.2
—
0.23
—
0
21
8
53
1.55
0.60
7.3
3.7
1.02
1.02
ratio
—
8
48
0
23
0.00
0.59
0.0
1.3
—
1.06
—
0
23
9
61
1.52
0.55
1.6
2.0
1.98
0.98
%
—
9
61
25
199
1.33
0.54
1.9
1.8
1266.22
1207.62
nmol/l
0.11
20
153
85
794
1.32
0.53
5.7
5.9
6.14
6.15
mmol/l
0.04
77
703
7
106
0.64
0.51
2.6
2.2
1.66
6.03
ug/l
—
7
87
29
239
1.29
0.50
8.5
4.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
6
42
1.45
0.36
1.0
1.2
—
—
—
0
0
7
55
1.29
0.30
2.4
3.3
36.93
36.94
°c
—
7
55
78
747
1.16
0.23
4.1
4.7
1.30
1.20
mmol/l
0.64
69
663
34
308
1.15
0.23
1.7
2.2
290.79
225.79
u/l
0.18
34
287
8
104
0.75
0.22
1.4
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
16
138
1.19
0.19
1.3
1.3
2.58
3.03
g/l
0.46
11
76
26
236
1.13
0.17
2.1
2.8
0.63
0.78
ug/l
0.58
16
164
18
159
1.16
0.16
1.3
1.2
1.04
1.17
u/ml
—
8
48
63
610
1.08
0.10
4.6
4.2
15.02
15.18
pmol/l
0.20
58
547
80
782
1.09
0.10
8.4
7.8
42.00
40.73
mmol/mol
0.60
75
711
6
57
1.06
0.08
1.3
1.3
—
—
—
0
0
7
63
1.12
0.08
1.3
1.6
—
—
—
0
0
81
800
1.05
0.03
5.3
6.7
2.44
2.49
mmol/l
0.17
76
724
18
187
0.96
0.01
1.6
1.5
1.50
1.43
mg/l
0.05
13
139
79
783
1.03
0.01
4.5
5.6
1.34
1.46
mmol/l
1.38
72
704
12
126
0.95
0.00
2.1
1.3
—
—
—
0
0
24
246
0.97
0.00
3.6
4.2
—
—
—
0
0
79
788
1.01
0.00
4.7
5.7
4.29
4.36
mmol/l
0.21
72
713
5
54
0.92
0.00
2.4
2.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
14
140
1.00
-0.00
1.9
1.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.0
—
0.62
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
5
57
0.87
-0.00
2.6
2.1
12.34
16.63
nmol/l
—
5
51
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: C3_URETER – Malignant neoplasm of ureter

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).